Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

CMS files CRUSH proposal to expand health programme fraud oversight

CMS’s new CRUSH proposal would tighten provider enrolment and reporting across federal health programmes, affecting clinical institutions.

Published 17 Nov 2026· 4 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

The Centers for Medicare & Medicaid Services filed a broad anti-fraud proposed rule on November 16, 2026, that would tighten provider enrolment, expand reporting and strengthen oversight across federal health programmes. For academic medical centres and university-affiliated clinical laboratories, the CRUSH proposal creates a new opportunity to assess how billing, ownership records and administrative systems would handle additional requirements.

CMS puts the CRUSH proposal on public inspection

The 545-page proposed rule, CMS-6098-P, is titled Comprehensive Regulations to Uncover Suspicious Healthcare. The Federal Register filing record shows it was filed at 4:15 p.m. Eastern time on November 16 and is scheduled for publication on November 19. Its provisions concern Medicare, Medicaid, the Children’s Health Insurance Program and the health-insurance Marketplace.

CMS describes the proposal as a package covering provider enrolment, medical review, investigations and programme-integrity oversight. The document requests comments and uses conditional language throughout: the proposed changes would take effect through a subsequent finalisation process. The immediate action for institutions is to examine the proposal and prepare any response, with the comment deadline tied to Federal Register publication.

Provider records and reporting would face tighter requirements

One concrete change concerns the reporting of enrolment information. CMS says current deadlines vary with the provider type and the information involved, with some changes reportable within 30 days and others within 90 days. The proposal would require all changes in enrolment information to be reported within 30 days. This includes administrative information beyond the ownership, practice-location and adverse-action changes already commonly subject to the shorter period.

The proposal also describes stronger identity verification, expanded grounds for enrolment denial and revocation, and a requirement for providers and suppliers billing Medicare Advantage to be enrolled in Original Medicare. Its Medicaid measures include additional provider-ownership reporting and stronger state oversight. These are distinct changes that an institution’s billing and compliance teams would need to map to the relevant participating entities and systems.

For managed-care oversight, CMS proposes mandatory referrals of substantiated or suspicious fraud, waste and abuse by Medicare Advantage organisations and Part D sponsors. It also proposes expanding reporting of payment suspensions based on credible fraud allegations beyond pharmacies to other provider and supplier types. The agency presents these measures as ways to improve the identification and handling of potentially inappropriate payments.

The filing follows an earlier request for information

CMS’s earlier CRUSH announcement sought stakeholder input on ways to prevent, detect and respond to fraud across the programmes it administers. That request for information had a March 30, 2026, comment deadline. The November filing advances the initiative from that information-gathering exercise to proposed regulatory text.

In a July 15 analysis, law firm Polsinelli identified the CRUSH initiative among forthcoming health-care rulemakings. Its analysis stressed that Unified Agenda dates are estimates and encouraged organisations to monitor agency activity, incorporate regulatory developments into planning and evaluate opportunities to comment. That earlier forecast provides context for the new filing; it is separate from a response to the November text.

Laboratory stakeholders previously urged targeted oversight

The Personalized Medicine Coalition’s March 30 comment letter supported efforts to stop fraudulent payments while warning against treating rising genetic- and molecular-testing use as evidence of fraud by itself. The coalition argued for an approach that distinguishes fraudulent operators from established laboratories performing medically appropriate clinician-ordered tests.

The coalition also raised concerns about potential administrative burdens and reimbursement disruption in the earlier request for information. Those comments show why laboratories have a direct stake in the initiative’s design. They are a dated stakeholder position on the earlier consultation, rather than a reaction to the newly filed proposal or evidence that every option discussed in March appears in the November text.

What university research and clinical offices should examine

The research-practice connection is institutional: universities may operate hospitals, clinical laboratories and clinical-research billing functions within organisations participating in these programmes. The useful first review is to identify the affected provider entities, the people responsible for keeping enrolment information current and the systems used to capture changes. A shorter reporting period would make handoffs between finance, compliance and operational teams particularly relevant.

Research offices working with clinical services can connect that review with their existing clinical-trial billing controls and background on false-claims exposure. These resources explain the surrounding administrative context. Institutional responses should identify specific proposed provisions and the operational evidence that supports their comments, rather than assume a general anti-fraud initiative changes every research billing arrangement in the same way.

Comments are due 60 days after publication

The proposed rule specifies a comment period ending 60 days after Federal Register publication and directs electronic comments to docket CMS-2026-0826 using file code CMS-6098-P. Institutions preparing a submission can use the publication-linked deadline in the document to organise their review. For the surrounding clinical billing context, CASRAI explains advance beneficiary notices in clinical trials. The proposal itself supplies the scope and instructions for this consultation.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →